Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
机构：
[1] Natl Clin Res Ctr Hematol Disorders, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Co, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Co, Blood Dis Hosp, Tianjin, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China
[7] Lunan Pharmaceut Grp Co LTD, Linyi, Shandong, Peoples R China
[8] Chinese Acad Med Sci, Blood Inst, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8038
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
    Mohty, Mohamad
    Tomasson, Michael H.
    Arnulf, Bertrand
    Bahlis, Nizar J.
    Prince, H. Miles
    Niesvizky, Ruben
    Rodriguez-Otero, Paula
    Martinez-Lopez, Joaquin
    Koehne, Guenther
    Jethava, Yogesh
    Gabayan, A. Eli
    Stevens, Don A.
    Nooka, Ajay K.
    Raje, Noopur S.
    Iida, Shinsuke
    Leip, Eric
    Conte, Umberto
    Czibere, Akos Gabor
    Viqueira, Andrea
    Lesokhin, Alexander M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma
    Rodriguez, Cesar
    D'Souza, Anita
    Shah, Nina
    Voorhees, Peter M.
    Ben Buelow
    Vij, Ravi
    Kumar, Shaji K.
    BLOOD, 2020, 136
  • [23] Long-Term Follow-Up From the MajesTEC-1 Study of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Garfall, Alfred L.
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca I.
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S25 - S26
  • [24] Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
    van de Donk, Niels
    Moreau, Philippe
    Garfall, Alfred
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay
    Martin, Thomas
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez Lopez, Joaquin
    Krishnan, Amrita
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S477 - S478
  • [25] Long-term follow-up from MajesTEC-1 of Teclistamab, a B-cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Donk, Van De N. W.
    Moreau, P.
    Garfall, A. L.
    Bhutani, M.
    Oriol, A.
    Nooka, A. K.
    Martin, T. G.
    Rosinol, L.
    Mateos, M. -V.
    Bahlis, N.
    Popat, R.
    Besemer, B.
    Lopez, Martinez J.
    Krishnan, A.
    Delforge, M.
    Trancucci, D.
    Verona, R., I
    Stephenson, T.
    Chastain, K.
    Sidana, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 124 - 124
  • [26] Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    van de Donk, Niels W. C. J.
    Moreau, Philippe
    Garfall, Alfred L.
    Bhutani, Manisha
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas G.
    Rosinol, Laura
    Mateos, Maria-Victoria
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Krishnan, Amrita Y.
    Delforge, Michel
    Trancucci, Danielle
    Verona, Raluca
    Stephenson, Tara
    Chastain, Katherine
    Sidana, Surbhi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] POPULATION PHARM ACOKINETICS (POPPK) OF ABBV-383, A B-CELL MATURATION ANTIGEN (BCMA) x CD3 BISPECIFIC T-CELL-REDIRECTING ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
    Polepally, A.
    Badillo, J.
    Rinas, M.
    Ahsan, A.
    Bueno, O.
    Talati, C.
    Menon, R.
    Engelhardt, B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S69 - S69
  • [28] Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Lesokhin, Alexander M.
    Levy, Moshe Y.
    Dalovisio, Andrew P.
    Bahlis, Nizar J.
    Solh, Melhem
    Sebag, Michael
    Jakubowiak, Andrzej
    Jethava, Yogesh S.
    Costello, Caitlin L.
    Chu, Michael P.
    Savona, Michael R.
    Gasparetto, Cristina
    Trudel, Suzanne
    Chou, Jeffrey
    Udata, Chandrasekhar
    Basu, Cynthia
    Krupka, Heike I.
    Raje, Noopur S.
    BLOOD, 2020, 136
  • [29] Correlative biomarker analyses for optimal therapeutic dose determination of ABBV-383, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM).
    Ahsan, Aarif
    Mantis, Christine
    Luo, Xizhi
    Zhang, Catherine C.
    Valdes, Cesar Rodriguez
    Voorhees, Peter M.
    D'Souza, Anita
    Chung, Alfred
    Tuchman, Sascha
    Safah, Hana
    Mckay, John T.
    Weisel, Katja C.
    Teipel, Raphael
    Korde, Neha
    Vij, Ravi
    Kumar, Shaji
    Bueno, Orlando Felix
    Pothacamury, Rajvineeth Kumar
    Talati, Chetasi
    Ross, Jeremy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.
    Touzeau, Cyrille
    Krishnan, Amrita Y.
    Moreau, Philippe
    Perrot, Aurore
    Usmani, Saad Zafar
    Manier, Salomon
    Cavo, Michele
    Martinez-Chamorro, Carmen
    Nooka, Ajay K.
    Martin, Thomas G.
    Karlin, Lionel
    Leleu, Xavier
    Bahlis, Nizar J.
    Besemer, Britta
    Pei, Lixia
    Verona, Raluca
    Girgis, Suzette
    Uhlar, Clarissa
    Kobos, Rachel
    Garfall, Alfred L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345